secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2025-09-17T23:59:59+00:00
Accession:  0001193125-25-205522
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio reports 99% T cell response rate in Phase 2 AMPLIFY-7P trial of ELI-002 7P
--------------------------------------------------------------------------------

- ELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90).
- Average fold increase 145.3x over baseline; median 44.3x; 80% of patients above 9.5x threshold correlated with clinical activity in Phase 1.
- 85% of patients had combined CD4+CD8 T cell response vs 75% in Phase 1; 67.4% responded to all 7 mKRAS antigens vs 50%.
- IDMC recommended continue without modifications after interim safety/efficacy review; company remains blinded to clinical outcomes.
- Final disease-free survival analysis anticipated in Q4 2025; Phase 2 includes both MRD+ and MRD- patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000119312525205522/0001193125-25-205522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000119312525205522/d38971d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-205522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer